Revolution Medicines (RVMD) TD Cowen 46th Annual Health Care Conference summary

Key value creation events and clinical trial updates

• Anticipated readout of the RASolute 302 trial in previously treated pancreatic cancer with daraxonrasib monotherapy versus chemotherapy in the first half of the year, expected to be a major milestone for the company.

• Five phase III studies are underway, four in pancreatic cancer, with progress in enrollment expected this year.

• Initial durability data for first-line pancreatic cancer cohorts (daraxonrasib monotherapy and combination with chemotherapy) expected in the first half of the year.

• Initial colorectal cancer data anticipated later in the year to inform registration strategy.

• Clarity on elironrasib (G12C inhibitor) development strategy expected as the year progresses.

RASolute 302 trial design and expectations

• The trial focuses on patients with G12 mutations (about 85% of pancreatic cancer cases), with initial statistical analysis centered on this cohort.

• Secondary analysis includes all pancreatic cancer patients, covering other mutations and non-RAS cases.

• The first analysis could be interim or final, depending on results, with possible outcomes including passing or not passing PFS and OS endpoints.

• Data will be shared in a scientific context after unblinding, with timing and content of disclosures dependent on results.

Translating results across treatment lines and trial enrollment

• RAS remains a key driver in pancreatic cancer across all lines of therapy, supporting the rationale for RAS inhibition in both first and later lines.

• Early data suggest encouraging impact of RAS inhibitors in first-line treatment, though cross-trial comparisons have limitations.

• Durability of response is emphasized as the most meaningful endpoint for patients.

• High demand for daraxonrasib is expected to support rapid enrollment in first-line trials once operationalized.